MG-K10 Shows Sustained Efficacy in Atopic Dermatitis Through 52 Weeks

Key Takeaways

• MG-K10 achieved significant improvements vs placebo at Week 16 and sustained high response rates through 52 weeks in moderate-to-severe atopic dermatitis (AD).
• Long-term data showed high proportions of patients achieving EASI-75 and IGA 0/1, including those switched from placebo.
• The therapy demonstrated a favorable safety profile with mostly mild-to-moderate adverse events and a potentially extended dosing interval.

A long-acting anti–IL-4 receptor alpha monoclonal antibody, MG-K10, demonstrated sustained efficacy and a favorable safety profile through 52 weeks in adults with moderate-to-severe atopic dermatitis (AD), according to results from a pivotal Phase 3 trial presented by Jianzhong Zhang, MD, PhD, at the American Academy of Dermatology (AAD) 2026 Annual Meeting.

MG-K10 targets IL-4Rα, inhibiting IL-4 and IL-13 signaling pathways central to type 2 inflammation in AD. Structural modification of the Fc region extends the drug’s half-life, enabling a 4-week dosing interval.

“It is more convenient to patients,” Dr. Zhang said, “and also we can see that the EASI-75 and IGS 0/1 reached a high level. That is the main advantage of this drug.”

The randomized trial (NCT06026891) enrolled 499 adults, assigned 2:1 to MG-K10 300 mg (with a 600 mg loading dose) or placebo every 4 weeks for 16 weeks, followed by a 36-week maintenance phase in which all patients received MG-K10.

At Week 16, MG-K10 met both co-primary endpoints, with significantly higher response rates than placebo for EASI-75 (59.8% vs 22.9%) and Investigator’s Global Assessment (IGA) 0/1 with ≥2-point improvement (32.7% vs 7.2%; both P < .0001). Secondary endpoints, including EASI-50, EASI-90, pruritus numerical rating scale, Dermatology Life Quality Index (DLQI), and Patient-Oriented Eczema Measure (POEM), also favored MG-K10.

Efficacy was maintained or improved through Week 52. Among patients who continued MG-K10, 94.3% achieved EASI-75 and 76.6% achieved IGA 0/1. Patients who crossed over from placebo demonstrated comparable outcomes (EASI-75: 90.9%; IGA 0/1: 73.4%), suggesting consistent benefit with longer-term treatment.

“These results support MG-K10 as a promising IL4Ra-targeted therapy for long-term management of atopic dermatitis,” Dr. Zhang said.

Safety findings over 52 weeks were favorable, with most adverse events classified as grade 1 or 2. No new safety signals were reported, and laboratory abnormalities were infrequent.